Skip to content
ABOUT
Accelerating Bio-Innovation
Royalty Pharma
SPEAKERS
AGENDA
PAST ABIs
2026
2025
2024
2023
2022
2019
ABI Sweden
AGENDA
LOCATIONS
ABOUT
SPEAKERS
Speakers
ABI27 MIT Speakers Coming Soon
Past ABI Presenters Have Included:
Scientific Luminaries
NOBEL
James Allison
MD Anderson Cancer Center
BREAKTHROUGH
Shankar Balasubramanian
University of Cambridge
NOBEL
Carolyn Bertozzi
Stanford University
Allan Bradley
University of Cambridge
Craig Crews
Yale University
Tyler Jacks
Koch Institute for Integrative Cancer Research at MIT
NOBEL
William Kaelin
Harvard Medical School
BREAKTHROUGH
Jeffery Kelly
The Scripps Research Institute
BREAKTHROUGH
Robert Langer
MIT
BREAKTHROUGH
David Liu
Harvard
Patrick Maxwell
University of Cambridge
Ira Mellman
Parker Institute for Cancer Immunotherapy (PICI)
NOBEL
Craig Mello
University of Massachusetts Medical School
PULITZER
Siddhartha Mukherjee
Columbia University
NOBEL
Venkatraman Ramakrishnan
MRC Laboratory Of Molecular Biology
BREAKTHROUGH
Michel Sadelain
Columbia University
Jude Samulski
Bamboo Therapeutics and Asklepios BioTherapeutics
BREAKTHROUGH
Charles Sawyers
Memorial Sloan Kettering
Georg Schett
FAU Erlangen-Nürnberg
Tim Springer
Harvard Medical School
NOBEL
Phillip Sharp
MIT
Kevan Shokat
University of California, San Francisco
Eric Topol
Scripps Research
NOBEL
Greg Winter
University of Cambridge
Industry Leaders
Karen Akinsanya
Schrödinger
Deborah Baron
Pfizer
Andrew Baum
Pfizer
Arie Belldegrun
Kite
Robert Blum
Cytokinetics
Jay Bradner
Amgen
Karin Conde-Knape
Novo Nordisk
Stan Crooke
n-Lorem Foundation
Robert M. Davis
Merck & Co
Bassil Dahiyat
Xencor
Richard Francis
Teva
Mark Goldsmith
Revolution Medicines
Henry Gosebruch
Abbvie
Yvonne Greenstreet
Alnylam Pharmaceuticals
Jane Grogan
Biogen
Steve Harr
Sana Biotechnology
Kate Haviland
Blueprint Medicines
Mary Lynne Hedley
Third Rock Ventures
Ying Huang
Legend Biotech
Bob Hugin
Celgene Corporation (retired)
William Lewis
Insmed
Ted Love
Global Blood Therapeutics
Mathai Mammen
Former JNJ
Nello Mainolfi
Kymera Therapeutics
John Maraganore
John F. Milligan
Gilead Sciences
Richard Pazdur
Center for Drug Evaluation and Research U.S. FDA
Andrew Plump
Takeda
David Redfern
GlaxoSmithKline
David M. Reese
Amgen
David A. Ricks
Eli Lilly and Company
Severin Schwan
Roche Holding
Laura Shawver
Capstan Therapeutics
Pascal Soriot
AstraZeneca
Marc Tessier-Lavigne
Xaira
Chris Viehbacher
Biogen
Tim Walbert
Horizon Therapeutics
Investors
Andy Acker
Janus Henderson Investors
Srini Akkaraju
Samsara BioCapital
Michael Anstey
Cambridge Innovation Capital
Christiana Bardon
MPM Capital
Kate Bingham
SV Health Managers
Tess Cameron
RA Capital
Judith Finegold
Capital Group
Simeon George
SR One
Phill Gross
Adage Capital Management
Andrew Hack
Bain Capital
Kris Jenner
Rock Springs Capital
Rajiv Kaul
Fidelity Investments
Adam Koppel
Bain Capital
Oleg Nodelman
EcoR1 Capital
Jason Rhodes
Atlas Ventures
Francesco De Rubertis
Medicxi
Amy Schulman
Polaris Venture Partners
Otello Stampacchia
Omega Funds
Rebecca Sykes
Wellington
Political Experts
Paul Begala
CNN
Mike Murphy
Karl Rove
In Collaboration with
Sally Kornbluth
MIT
Deborah Prentice
University of Cambridge
Anantha P. Chandrakasan
MIT
John Aston
University of Cambridge